“Audience of children is the most common choice of most of us, but parents of pregnancy do not see how genetic risks could affect their future child,” she said. Noor Siddiqui, Founder and CEO of Orchid. “With Orchid’s ultra-high-resolution reports, expectant parents can now conceive confidently, prepared with information and guidance to give their children better opportunities for healthy living.”
Orchid now invites couples to join the waiting list and get early access to the Orchid Couples report.
The Orchid Pairs Report is a genetic test that couples can perform at home by sending saliva samples approved by a doctor. It reveals whether a couple can pass on to their future children an increased genetic risk for 10 major diseases: heart disease, stroke, atrial fibrillation, schizophrenia, Alzheimer’s disease, breast cancer, prostate cancer, type 2 diabetes, type 1 diabetes and inflammatory bowel disease. The report analyzes 100% of the genome of both partners and models the DNA combination combinations of both partners in the unborn child.
“If you knew you could know data that could protect your child’s health, the worst fear and regret is for parents,” said Dr. Ruben Alvero, a highly sought after fertility doctor, obstetrician and gynecologist, and reproductive endocrinologist and infertility doctor. “The orchid helps alert you to genetic risks at an early stage that can negatively affect your child’s long-term health. Armed with this information, expectant parents can proactively manage their health and make informed reproductive decisions. Last but not least, I’m excited to offer to my patients soon. this screening option. ”
The Orchid Couple Report also includes a report for each partner that detects an individual risk for a particular disease. There are three reports – a couple report detailing the risks to future children, a male partner report and a partner report. “As soon as I tried Orchid, I knew how valuable it would be for other couples. If we have data on how our genetics will affect our child, it allows us to make better decisions as parents. This is a company that really wants to change the lives of many people and the quality of life for the better and I am really excited about participating. “added Leviner’s leg, Angel Orchid Investor and CEO of Picnic Health.
Previously, genetic testing before conception analyzed only 2% of the genome of only one partner and was able to detect only rare genetic disorders affecting approximately 1% of the population. In contrast, Orchid analyzes the entire genome of both partners and assesses the genetic predisposition to diseases that affect more than 60% of the population.
“So far, parents have only been able to genetically screen for rare events with a chance of 1 in 1,000 or even 1 in a million. However, potential parents have by no means been able to measure their future child’s genetic predisposition to much more common chronic diseases,” debilitating diseases based on their combined genetics. , “said the director ART Institute of Washington and orchid consultant Jacques Cohen, “Orchid now realizes this test at home.”
To date, measuring genetic predisposition to disease has not been possible at the peak because genetic data sets were not previously large enough to identify the millions of variants that together contribute to the risk of major diseases. “The orchid is a breakthrough in pre-conception testing that allows parents to protect their children from many types of inherited diseases.” he said Balaji Srinivasan, co-founder of genetic testing firm Counsyl and former general partner at Andreessen Horowitz, “is a step forward from traditional Mendelian genetic testing by testing multifactorial conditions that affect the majority of the population.”
In addition to being a category-defining technology, Orchid seeks to address a major challenge in healthcare: the prevalence of chronic diseases. Today, more than 100 million Americans live with a chronic disease with limited treatment options. The orchid makes it possible to reduce the risk of developing the disease by quantifying previously unknown genetic risks and by adapting guidelines for lifestyle changes. Later this year, Orchid will also offer further embryo health reports that will allow parents to reduce the genetic risk of their unborn child by creating embryos by in vitro fertilization and implanting embryos in an order that can reduce the risk of developing the disease.
“Genetics affects everyone’s health, but most of us are unaware of our unique genetic makeup, including health risks. Through the use of population genetics, statistical modeling, reproductive technologies, and the latest advances in genomic science, the Orchid will give many the opportunity to be parents and help themselves with science to improve the genomic health of their families, “said dr. Carlos D. Bustamante, award-winning MacArthur Stanford a population geneticist and a vocal advocate of consumer choice in healthcare. “Having been a consultant, investor and active participant in genomics for over twenty years, I recognize this as an important moment in reproductive rights for all and I am proud to have worked with the future Orchid team as an early investor and consultant.”
“Often in healthcare, we treat the symptoms instead of hitting the root,” he said Brian Armstrong, Coinbase CEO and angel investor. “The orchid is a categorical change. It’s a step towards where we need to go in medicine – away from controlling chronic disease and anticipating and preventing it. With Orchid, parents can do it from birth, which is an important step in the right direction.”
The orchid is meant to be accessible to anything that could benefit; applications for financial assistance are available here. The orchid also builds resources for fertility and genetics education and a forum for wider community discussion. “We are in an age of seismic change in biotechnology – the ability to sequence the genome, the ability to edit genes and the now unparalleled ability to influence the health of the unborn child. The orchid is here to advocate the most thoughtful and careful and thoughtful approach,” Siddiqui said.
The orchid helps couples to have healthy babies. The orchid makes it easier for couples to see how their genetics will affect the health of their future child by quantifying their genetic predisposition to disease. The Orchid Pairs Report is a genetic test based on saliva at home to determine if a future child has a normal or increased risk of disease. Couples at higher risk can opt for IVF and mitigate the risk through further embryo health reports. Later this year, the orchid report on embryos will allow couples pursuing in vitro fertilization and their doctors to implant embryos in an order that reduces the risk of developing the disease.
Noor Siddiqui founded the Orchid to reduce suffering and increase the chances of the next generation living a life undisturbed by disease. 45% of Americans struggle with incurable health problems, and couples care for their children suffering from the same diseases. Orchid addresses this huge issue by giving prospective parents the information they need to protect their children’s health.